212 related articles for article (PubMed ID: 36413364)
41. [Estimating standard performance measures of opportunistic screening for prostate cancer].
Leoni M; Falcini F; Ravaioli A; Foca F; Andalò G; Benini F; Dal Pozzo C; Ricci R; Naldoni C; Bucchi L
Epidemiol Prev; 2008; 32(6):285-93. PubMed ID: 19353962
[TBL] [Abstract][Full Text] [Related]
42. Association of the USPSTF Grade D Recommendation Against Prostate-Specific Antigen Screening With Prostate Cancer-Specific Mortality.
Burgess L; Aldrighetti CM; Ghosh A; Niemierko A; Chino F; Huynh MJ; Efstathiou JA; Kamran SC
JAMA Netw Open; 2022 May; 5(5):e2211869. PubMed ID: 35576008
[TBL] [Abstract][Full Text] [Related]
43. Cost implications of PSA screening differ by age.
Rao K; Liang S; Cardamone M; Joshu CE; Marmen K; Bhavsar N; Nelson WG; Ballentine Carter H; Albert MC; Platz EA; Pollack CE
BMC Urol; 2018 May; 18(1):38. PubMed ID: 29743049
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of Spending Differences Between Beneficiaries in Medicare Advantage and the Medicare Shared Savings Program.
Parikh RB; Emanuel EJ; Brensinger CM; Boyle CW; Price-Haywood EG; Burton JH; Heltz SB; Navathe AS
JAMA Netw Open; 2022 Aug; 5(8):e2228529. PubMed ID: 35997977
[TBL] [Abstract][Full Text] [Related]
45. Patient Cost-Sharing and Utilization of Breast Cancer Diagnostic Imaging by Patients Undergoing Subsequent Testing After a Screening Mammogram.
Hughes DR; Espinoza W; Fein S; Rula EY; McGinty G
JAMA Netw Open; 2023 Mar; 6(3):e234893. PubMed ID: 36972047
[TBL] [Abstract][Full Text] [Related]
46. Use and Cost of Low-Value Health Services Delivered or Paid for by the Veterans Health Administration.
Radomski TR; Zhao X; Lovelace EZ; Sileanu FE; Rose L; Schwartz AL; Schleiden LJ; Oakes AH; Pickering AN; Yang D; Hale JA; Gellad WF; Fine MJ; Thorpe CT
JAMA Intern Med; 2022 Aug; 182(8):832-839. PubMed ID: 35788786
[TBL] [Abstract][Full Text] [Related]
47. The Cost-Effectiveness of Prostate Cancer Detection with the Use of Prostate Health Index.
Heijnsdijk EA; Denham D; de Koning HJ
Value Health; 2016; 19(2):153-7. PubMed ID: 27021748
[TBL] [Abstract][Full Text] [Related]
48. Number of prostate-specific antigen (PSA) screening tests in the last five years reported by men in the United States in 2010, 2015, and 2018.
Richards TB; Dai S; Gray SC; Hall IJ; Siegel DA
Urol Oncol; 2022 May; 40(5):192.e19-192.e25. PubMed ID: 35236620
[TBL] [Abstract][Full Text] [Related]
49. Prostate-specific antigen (PSA) screening and follow-up investigations in Māori and non-Māori men in New Zealand.
Obertová Z; Scott N; Brown C; Hodgson F; Stewart A; Holmes M; Lawrenson R
BMC Fam Pract; 2014 Aug; 15():145. PubMed ID: 25154420
[TBL] [Abstract][Full Text] [Related]
50. PSA Screening for Prostate Cancer: Why Saying No is a High-Value Health Care Choice.
Wilt TJ; Dahm P
J Natl Compr Canc Netw; 2015 Dec; 13(12):1566-74. PubMed ID: 26656523
[TBL] [Abstract][Full Text] [Related]
51. Variation in prostate-specific antigen screening in men aged 80 and older in fee-for-service Medicare.
Bynum J; Song Y; Fisher E
J Am Geriatr Soc; 2010 Apr; 58(4):674-80. PubMed ID: 20345867
[TBL] [Abstract][Full Text] [Related]
52. The impact of PSA testing frequency on prostate cancer incidence and treatment in older men.
Shao YH; Albertsen PC; Shih W; Roberts CB; Lu-Yao GL
Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):332-9. PubMed ID: 21709691
[TBL] [Abstract][Full Text] [Related]
53. Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States.
Drazer MW; Huo D; Schonberg MA; Razmaria A; Eggener SE
J Clin Oncol; 2011 May; 29(13):1736-43. PubMed ID: 21444863
[TBL] [Abstract][Full Text] [Related]
54. Prevalence of prostate specific antigen testing for prostate cancer in elderly men.
Dyche DJ; Ness J; West M; Allareddy V; Konety BR
J Urol; 2006 Jun; 175(6):2078-82. PubMed ID: 16697807
[TBL] [Abstract][Full Text] [Related]
55. Factors associated with prostate specific antigen testing in Australians: Analysis of the New South Wales 45 and Up Study.
Nair-Shalliker V; Bang A; Weber M; Goldsbury DE; Caruana M; Emery J; Banks E; Canfell K; O'Connell DL; Smith DP
Sci Rep; 2018 Mar; 8(1):4261. PubMed ID: 29523809
[TBL] [Abstract][Full Text] [Related]
56. Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey.
Mariotto AB; Etzioni R; Krapcho M; Feuer EJ
Cancer; 2007 May; 109(9):1877-86. PubMed ID: 17372918
[TBL] [Abstract][Full Text] [Related]
57. Changes in prostate specific antigen (PSA) "screening" patterns by geographic region and socio-economic status in Australia: Analysis of medicare data in 50-69 year old men.
Kohar A; Cramb SM; Pickles K; Smith DP; Baade PD
Cancer Epidemiol; 2023 Apr; 83():102338. PubMed ID: 36841020
[TBL] [Abstract][Full Text] [Related]
58. Effectiveness of Medicare cost-sharing elimination for Cancer screening on utilization.
Xu WY; Wickizer TM; Jung JK
BMC Health Serv Res; 2019 Jun; 19(1):392. PubMed ID: 31208422
[TBL] [Abstract][Full Text] [Related]
59. Screening for prostate cancer: updated experience from the Tyrol study.
Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
